What actually happens inside a dog's heart with mitral valve disease?

Myxomatous mitral valve disease, sometimes called endocardiosis, is a slow degeneration of the valve leaflets separating the heart's left atrium and left ventricle. The leaflets thicken, become nodular, and can no longer close tightly, so a portion of blood is pushed backward into the atrium every time the heart contracts. The Cornell Riney Canine Health Center notes that this condition accounts for roughly three-quarters of all heart disease diagnosed in dogs, making it by far the most frequent cardiac finding in general practice (Cornell Riney Canine Health Center, 2023).

Over months to years, that backward leak, called regurgitation, forces the left atrium and ventricle to enlarge as they compensate for the inefficient blood flow. The American College of Veterinary Internal Medicine's consensus staging system classifies dogs from Stage A, meaning at risk but no disease, through Stage D, meaning advanced heart failure resistant to standard therapy, and this staging guides exactly when treatment should start (ACVIM, 2019).

Which dog breeds are most likely to develop this condition, and at what age?

Small and toy breeds carry the highest risk, with Cavalier King Charles Spaniels affected earlier and more severely than almost any other breed; some studies cited by the AKC Canine Health Foundation report murmurs detectable in over half of Cavaliers by age 5 and in nearly all of them by age 10 (AKC Canine Health Foundation, 2022). Dachshunds, Chihuahuas, poodles, and Boston terriers are also frequently diagnosed, typically after age 8.

Prevalence climbs steadily with age across small breeds generally, and males appear to develop clinically significant disease somewhat more often and earlier than females, according to the Merck Veterinary Manual (Merck Veterinary Manual, 2023). Large-breed dogs can develop mitral valve disease too, but it is far less common and tends to appear alongside other cardiac conditions rather than as a primary diagnosis.

What is usually the very first sign an owner or vet notices?

In the vast majority of cases, the earliest detectable sign is a left-sided systolic heart murmur picked up during a routine physical exam, long before the dog shows any outward symptoms at home. Veterinarians grade these murmurs on a scale of I to VI based on loudness and the presence of a palpable vibration, and murmur intensity tends to correlate loosely with disease severity (Merck Veterinary Manual, 2023).

Dogs in the early, compensated stage often act completely normal, eating, playing, and exercising without any visible change, which is why annual or twice-yearly veterinary exams matter even in outwardly healthy small-breed seniors. A murmur alone doesn't confirm heart failure, but it is the signal that triggers further workup, including chest X-rays or an echocardiogram to measure how much the heart chambers have enlarged.

How do veterinarians confirm the diagnosis and determine its severity?

Echocardiography is the diagnostic gold standard, allowing a cardiologist to directly visualize the thickened valve leaflets, measure the degree of regurgitation with Doppler imaging, and calculate the left atrium-to-aorta ratio, a key number used to judge how enlarged the heart has become (Cornell Riney Canine Health Center, 2023). Chest radiographs complement this by tracking overall heart size through the vertebral heart score and by checking the lungs for early fluid buildup.

Blood tests measuring NT-proBNP, a hormone released when heart muscle is stretched, can help flag dogs whose disease is progressing even before radiographs show clear changes, and this marker is increasingly used to decide when to start medication (ACVIM, 2019). Blood pressure measurement and bloodwork are also typically included to rule out other conditions that can mimic or worsen cardiac symptoms.

What treatments actually slow the disease or extend a dog's life?

Pimobendan, sold under the brand name Vetmedin, is the cornerstone drug for dogs with significant heart enlargement, since it both strengthens the heart's contraction and relaxes blood vessels to ease the workload on the failing valve. The landmark EPIC trial found that starting pimobendan in dogs with enlarged hearts but no symptoms yet delayed the onset of congestive heart failure by a median of about 15 months compared with placebo (ACVIM, 2019).

Once congestive heart failure develops, treatment typically adds a diuretic such as furosemide to clear fluid from the lungs, along with an ACE inhibitor like enalapril or benazepril to reduce strain on the heart; some dogs also receive spironolactone for its added cardiac benefits. The Merck Veterinary Manual notes that dogs managed on this combination therapy after developing heart failure commonly survive roughly 9 to 18 months, though individual outcomes vary widely depending on how advanced the disease was at diagnosis (Merck Veterinary Manual, 2023).

What can owners do at home to manage a dog with this diagnosis day to day?

Counting resting or sleeping respiratory rate at home, ideally under 30 breaths per minute, is one of the most useful monitoring tools available to owners and is recommended by veterinary cardiologists as an early warning system for fluid buildup in the lungs (Cornell Riney Canine Health Center, 2023). A gradual upward trend over several days, even before coughing starts, often prompts a medication adjustment that prevents a full crisis.

Moderate, low-impact exercise is generally fine and even encouraged for dogs in earlier stages, while dogs in active heart failure need rest and a controlled environment with minimal exertion. Weight management matters too, since excess body weight increases cardiac workload, and some vets recommend a moderately sodium-restricted diet once heart failure develops, though this should be tailored individually rather than applied to every dog with a murmur (AAHA, 2019).

What does the long-term outlook look like after diagnosis?

Many dogs diagnosed at the murmur-only stage, with no heart enlargement yet, live for years without needing medication beyond periodic rechecks every 6 to 12 months to monitor for progression. Once significant enlargement is confirmed by echocardiogram, starting pimobendan proactively has been shown to meaningfully extend the symptom-free period before heart failure sets in (ACVIM, 2019).

Overall survival varies enormously by breed, age at diagnosis, and how quickly the disease is progressing, but the general trend documented by the AKC Canine Health Foundation is that dogs diagnosed and treated according to current staging guidelines live longer and stay more comfortable than those managed only after severe symptoms appear (AKC Canine Health Foundation, 2022). Regular cardiology follow-up, rather than a one-time diagnosis, is what allows treatment to be adjusted as the disease naturally advances through its stages.